<div id="readability-page-1"><div>CIMG Inc., a company engaged in the production and distribution of health and wellness products, has released its annual Form 10-K report, detailing significant financial growth, strategic initiatives, and the challenges it faces. The report highlights the company's impressive revenue growth, expansion into new product lines, and strategic efforts to enhance its market presence and operational efficiency. Financial Highlights Total Revenue: $10.30 million, representing a growth of 433.48% compared to the previous fiscal year, primarily driven by the inclusion of revenues from the Homology of Medicine and Food Series and the Computing Power Product Series.Gross Profit: $0.13 million, an increase from $0.03 million in the previous fiscal year, attributed to higher revenue from newly acquired entities.Net Loss: $4.89 million, a decrease from a net loss of $8.97 million in the previous fiscal year, primarily due to lower operating expenses, including reductions in labor costs, professional fees, and office expenses. Business Highlights Revenue Segments: The company reported revenue from three main product series: the Homology of Medicine and Food Series, the Computing Power Product Series, and the Maca Product Series. The Homology of Medicine and Food Series contributed 61.65% of total revenue, the Computing Power Product Series contributed 36.94%, and the Maca Product Series contributed 1.41%.Geographical Performance: The company has expanded its operational footprint and distribution capabilities in Hong Kong, the PRC, and other Asian markets. This expansion is supported by acquisitions and partnerships with local distributors.New Product Launches: In July 2024, the company launched the 'Homology of Medicine and Food' series, which includes Huomao-branded products, exosome eye drops, and other health and wellness products. In September 2025, the company introduced the 'Computing Power Product' series, offering hardware devices with AI data-processing modules.Sales Units: The company distributes its products through wholesale channels, including grocery stores, convenience stores, and vending machines. The Maca Series products are primarily sold through these channels, with plans to expand retail operations and leverage digital technologies.Future Outlook: The company plans to expand its product offerings, including new Maca-based products and additional items in the Homology of Medicine and Food series. It also aims to increase its global presence, particularly in Asia, North America, and Europe, and enhance brand awareness through digital marketing and strategic partnerships. Strategic Initiatives Strategic Initiatives: CIMG Inc. has been undergoing a transformation in digital marketing, distribution, and sales since July 2024. The company has expanded its sales and distribution network to include Maca-infused food and beverages, and launched the 'Homology of Medicine and Food' series, which contributed to sales growth. Additionally, in September 2025, CIMG launched the 'Computing Power Product' series, providing hardware devices with AI data-processing modules tailored to industry needs.Capital Management: The company has funded its operations primarily through proceeds from registered public offerings and private placements of its Common Stock. Cash provided from financing activities increased significantly from $9,586,272 in 2024 to $17,247,540 in 2025, mainly due to a rise in private placements. CIMG has not paid dividends and does not anticipate paying any in the foreseeable future, intending to retain earnings for business development. The company also faced Nasdaq listing deficiencies but has regained compliance with several Nasdaq Listing Rules as of December 2025.Future Outlook: CIMG plans to alleviate substantial doubt about its ability to continue as a going concern by seeking additional funding through public or private equity financings and other capital-raising activities. The company remains focused on leveraging technology and data-driven marketing tools to support product promotion and sales, with a commitment to responsible and sustainable sourcing. The company is optimistic about achieving sales growth and enhancing enterprise value through its comprehensive digital marketing strategy. Challenges and Risks Financial Condition and Capital Requirements: The company has a history of net losses and expects to continue incurring losses. The independent auditor's report includes a substantial doubt about the company's ability to continue as a going concern without additional financing. Future changes in financial accounting standards may also cause unexpected financial reporting fluctuations.Business Risks: The company's business is highly concentrated in its Maca Series products, relying on a limited number of suppliers and customers, which exposes it to significant risks. Product safety and quality concerns, increased competition, and changes in the retail landscape could negatively impact the business. The company also faces challenges in managing future growth effectively and accurately forecasting customer demand.Regulatory Risks: The company operates internationally and is subject to complex legal and regulatory requirements, including those related to product labeling and marketing claims. Non-compliance could adversely affect the business. Additionally, the PRC government's policies and regulations could significantly impact the company's operations in China.Geopolitical Risks: Ongoing geopolitical tensions, particularly between the United States and China, may have a material adverse effect on the company's business, financial condition, and results of operations. Tariffs and trade policies could impact the company's supply chain and market access.Digital Assets and AI Risks: The company has introduced new revenue streams related to digital assets and artificial intelligence, which come with risks such as regulatory uncertainty, volatility, and cybersecurity concerns. Changes in blockchain validation protocols or regulatory interpretations could reduce the value of the company's digital asset holdings.SEC Filing: CIMG Inc. [ IMG ] - 10-K - Feb. 13, 2026</div></div>

CIMG

CIMG Inc. has released its annual Form 10-K report, showcasing significant financial growth with total revenue of $10.30 million, a 433.48% increase from the previous year. The report highlights strategic initiatives, including new product launches and expansion into Asian markets. Despite a net loss of $4.89 million, the company has improved its financial condition and regained compliance with Nasdaq listing rules. Future plans include expanding product offerings and enhancing global presence, while facing challenges such as reliance on key suppliers and regulatory risks.

CIMG Inc. SEC 10-K Report